Pfizer intends to sell 2018, 2019, 2021 and 2026 notes, reissue 4.4% notes due 2044

By Lisa Kerner

Charlotte, N.C., May 31 – Pfizer Inc. is offering new unsecured notes due 2018, 2019, 2021 and 2026.

The company is also offering a further issuance of its $500 million 4.4% notes due 2044 initially issued on May 15, 2014, according to a 424B3 filing with the Securities and Exchange Commission. The new 4.4% notes will be fully fungible with the original notes.

Barclays, Goldman Sachs & Co., J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are the bookrunners.

Proceeds will be used for general corporate purposes and to repay outstanding commercial paper.

Pfizer is a biopharmaceutical company based in New York.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.